Renin-angiotensin system blockade reduces cardiovascular events in nonheart failure, stable patients with prior coronary intervention

Coronary Artery Disease
Young ChoiKiyuk Chang

Abstract

The effects of renin-angiotensin system (RAS) blockade on the clinical outcome in patients with stable coronary artery disease (SCAD) are conflicting. We evaluated the long-term effects of RAS blockers (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) on the clinical outcomes in patients with SCAD without heart failure (HF) who underwent percutaneous coronary intervention (PCI) with drug-eluting stent using a large-scale, multicenter, prospective cohort registry. A total of 5722 patients with SCAD were enrolled and divided into two groups according to the use of RAS blockers after PCI: RAS blocker group included 4070 patients and no RAS blocker group included 1652 patients. Exclusion criteria were left ventricular ejection fraction less than 50% and the history of HF or myocardial infarction. A major adverse cardiovascular event (MACE) was defined as a composite of cardiovascular death, nonfatal myocardial infarction, and stroke. During a median follow-up of 29.7 months, RAS blockers were associated with a significant reduction in the risk of MACE [adjusted hazard ratio (HR): 0.781; 95% confidence interval (CI): 0.626-0.975; P=0.015] and all-cause death (adjusted HR: 0.788; 95% CI: 0.627-0.990; P=0.041) ...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Jan 11, 2003·The American Journal of Cardiology·Flavio RibichiniEugenio Uslenghi
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
Oct 27, 2005·European Heart Journal·Sjoerd H HofmaPatrick W Serruys
Jun 21, 2006·The American Journal of Cardiology·Carlos M Ferrario, William B Strawn
Jan 26, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Soichiro FukeTohru Ohe
Jan 15, 2015·European Journal of Clinical Investigation·Analina R da SilvaFrançois Mach
Dec 24, 2015·Coronary Artery Disease·Suk-Min SeoUNKNOWN CathOlic University of Korea – percutAneous Coronary inTervention registry investigators
May 18, 2016·Therapeutic Advances in Cardiovascular Disease·Zhuang Xiao-DongDu Zhi-Min

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.